Joshua Griffin, MD
Urology · Oxford, MSNPI 1770771743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,286 of the $6,053 with a category attached, or 87.3%. It is spread thinly across 36 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,534 and has fallen 74.0% since, to $400 in 2025.
Across 265 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$975
- Procept Biorobotics Corporation$928
- Johnson & Johnson$821
- Boston Scientific$479
- Sumitomo Pharma America, Inc.$412
- Dendreon Pharmaceuticals LLC$392
- plus $2K from 30 others
What the payments were for
- Travel & lodging$4778%
- Food & beverage$5,28687%
- Education$2915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 62 | $975 |
| Procept Biorobotics Corporation | 12 | $928 |
| Johnson & Johnson | 42 | $821 |
| Boston Scientific | 18 | $479 |
| Sumitomo Pharma America, Inc. | 17 | $412 |
| Dendreon Pharmaceuticals LLC | 12 | $392 |
| Neotract Inc. | 3 | $269 |
| Myovant Sciences Inc. | 14 | $234 |
| AbbVie(2 entities) | 12 | $185 |
| Pfizer | 11 | $180 |
| Urogen Pharma, Inc. | 6 | $98 |
| Myriad Genetic Laboratories, Inc. | 5 | $96 |
| Endo Pharmaceuticals Inc. | 3 | $90 |
| Rochester Medical Corporation | 4 | $87 |
| Bayer | 5 | $81 |
| Antares Pharma, Inc. | 4 | $74 |
| Coloplast | 3 | $67 |
| Teleflex LLC | 4 | $65 |
| Tempus AI, Inc | 3 | $58 |
| Travere Therapeutics, Inc. | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| Olympus America Inc. | 2 | $47 |
| Merck | 2 | $40 |
| Novartis | 2 | $39 |
| Blue Earth Diagnostics | 2 | $37 |
| Intuitive Surgical | 1 | $29 |
| Ambu Inc. | 1 | $26 |
| Endo USA, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Richard Wolf Medical Instruments Corp. | 1 | $18 |
| AstraZeneca | 1 | $14 |
| Axonics, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Photocure Inc | 1 | $13 |
| Dentsply IH Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$687
- PROVENGE$124
- RYBREVANT$121
- CARVYKTI$121
- Erleada$109
How this compares
$6,053 in reported general payments places this provider in the 70th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 75 | $1,048,208 |
| ErleadaApalutamide | 43 | $625,950 |
| OrgovyxRelugolix | 11 | $29,316 |
| GemtesaVibegron | 41 | $28,418 |
| MyrbetriqMirabegron | 37 | $19,221 |
| Tamsulosin Hcl | 288 | $2,310 |
| Finasteride | 161 | $1,412 |
| Testosterone Cypionate | 18 | $454 |
| Solifenacin Succinate | 14 | $420 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $337 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $303 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $254 |
| Doxazosin Mesylate | 20 | $208 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $128 |
| Ciprofloxacin Hcl | 57 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $975 | $1,067,429112 claims |
| Johnson & JohnsonErleada | $821 | $625,95043 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $412 | $57,73552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 94 urology providers in Mississippi.
Other urology in Oxford
- Brent HardinOxford$4K
- Doyle RenfroeOxford$4K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Patrick DailyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.